Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2016 / Cilt: 69 - Sayı: 3

Additional Agents in Ovulation Induction

Ovülasyon İndüksiyonunda Ek Ajanlar

Pages
217–222
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this sense, the best known ad- ditional agents are metformin, aromatase inhibitors, dehydrepiandrosterone, androgens, growth hormone, corticosteroids, and antioxidants.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite all advancement in ovarian stimulation programmes and laboratory techniques, the success of assis- ted reproductive techniques remains limited.
📊
Key Findings & Data:Today, the primary stimulating agents adopted as standard are clomiphene citrate and gonadotrophins.
💡
Conclusion & Impact:In this sense, the best known ad- ditional agents are metformin, aromatase inhibitors, dehydrepiandrosterone, androgens, growth hormone, corticosteroids, and antioxidants.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Despite all advancement in ovarian stimulation programmes and laboratory techniques, the success of assis- ted reproductive techniques remains limited. Today, the primary stimulating agents adopted as standard are clomiphene citrate and gonadotrophins. In some patients treated with stimulation protocols using those two agents, adequate follicular development cannot be maintained or adequate amount and/or quality of oocy- tes cannot be achieved. Hence, development of some alternative treatment strategies in assisted reproduc- tive technologies has been needed. Nowadays, those treatment methods are used in anovulatory infertile patients and poor responders. Some additional agents are used in those patients in order to increase the amount and quality of achieved oocytes while decreasing treatment costs. In this sense, the best known ad- ditional agents are metformin, aromatase inhibitors, dehydrepiandrosterone, androgens, growth hormone, corticosteroids, and antioxidants.

Özet

Ovaryen stimülasyon programlarında ve laboratuar tekniklerinde sağlanan tüm gelişmelere rağmen, yardımlı üreme tekniklerinin başarısı günümüzde hala sınırlıdır. Günümüzde standart olarak kabul edilen temel stimü- lan ajanlar klomifen sitrat ve gonadotropinlerdir. Bu iki ajanın kullanıldığı stimülasyon protokollerinde bazı hastalarda yeterli folikül gelişimi sağlanamamakta veya yeterli sayıda ve/veya kalitede oosit elde edilememek- tedir. Bu nedenle, yardımlı üreme tekniklerinde alternatif bazı tedavi stratejilerinin geliştirilmesine gerek du- yulmuştur. Bu tedaviler günümüzde yaygın olarak anovulatuar infertil ve kötü over yanıtı gösteren hastalarda kullanılmaktadır. Bu hastalarda hem elde edilen oositin sayısını ve kalitesini arttırmak için hem de tedavi ma- liyetini düşürmek için bazı ek ajanlar kullanılmaktadır. Bu bağlamda, bu ajanlardan en iyi bilinenleri metfor- min, aromataz inhibitörleri, dehidroepiandrosteron, androjenler, büyüme hormonu, kortikosteroidler ve antioksidanlardır.

🔖

Cite This Article

ŞÜKÜR, Y. E., KAHRAMAN, K., ATABEKOĞLU, C. S. (2022). Additional Agents in Ovulation Induction. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 69 - Sayı: 3, 217–222. https://ajindex.com/articles/443747

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 25; 338: 1876-1880.
  2. Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene cit- rate in patients with polycystic ovary synd- rome who are resistant to clomiphene cit- rate alone. Fertil Steril. 2001;75:310-315.
  3. Batukan C, Baysal B. Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch Gy- necol Obstet 2001; 265: 124-127.
  4. Kocak M, Caliskan E, Simsir C, et al. Met- formin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clo- miphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril. 2002; 77: 101-106.
  5. Sturrock ND, Lannon B, Fay TN. Metfor- min does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002; 53: 469-473.
  6. Moll E, Bossuyt PM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on in- duction of ovulation in women with newly diagnosed polycystic ovary syndrome: ran- domised double blind clinical trial. BMJ 2006; 332: 1485. Tang T, Lord JM, Norman RJ, et al. Insu- lin-sensitising drugs (metformin, rosiglita- zone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010; 20: CD003053. Creanga AA, Bradley HM, McCormick C, et al. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gyne- col 2008; 111: 959-968. De Leo V, la Marca A, Ditto A, et al. Ef- fects of metformin on gonadotropinindu- ced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999; 72: Palomba S, Falbo A, Orio F jr, et al. A ran- domized controlled trial evaluating met- formin pretreatment and co-administra- tion in nonobese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian hyperstimulation plus timed intercourse or intra-uterine in- semination. Hum Reprod 2005; 20: 2879- 2886. Stadtmauer LA, Toma SK, Riehl RM, et al.Impact of metformin therapy on ova- rian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing in-vitro fertilization. Reprod Biomed Online 2002; 5: 112-116.
  7. Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in w